cabozantinib and Neurofibromatosis-1

cabozantinib has been researched along with Neurofibromatosis-1* in 1 studies

Trials

1 trial(s) available for cabozantinib and Neurofibromatosis-1

Article	Year
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nature medicine, 2021, Volume: 27, Issue:1 Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1 Topics: Adolescent; Adult; Anilides; Animals; Disease Models, Animal; Female; Genes, Neurofibromatosis 1; Humans; Male; Mice; Mice, Mutant Strains; Neurofibroma, Plexiform; Neurofibromatosis 1; Pain Measurement; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Quality of Life; Receptor Protein-Tyrosine Kinases; Translational Research, Biomedical; Young Adult	2021

Article

Year

Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.

Nature medicine, 2021, Volume: 27, Issue:1

Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1

Topics: Adolescent; Adult; Anilides; Animals; Disease Models, Animal; Female; Genes, Neurofibromatosis 1; Humans; Male; Mice; Mice, Mutant Strains; Neurofibroma, Plexiform; Neurofibromatosis 1; Pain Measurement; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Quality of Life; Receptor Protein-Tyrosine Kinases; Translational Research, Biomedical; Young Adult

2021